首页 > 最新文献

International journal of cardiology. Congenital heart disease最新文献

英文 中文
Corrigendum to [Int J Cardiol Congenit Heart Dis 9 September 2022 100394] 对[Int J Cardiol Congenit Heart Dis 9 September 2022 100394]的更正
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.ijcchd.2024.100516
{"title":"Corrigendum to <Surgical pulmonary valve replacement at a tertiary adult congenital heart centre in the current era> [Int J Cardiol Congenit Heart Dis 9 September 2022 100394]","authors":"","doi":"10.1016/j.ijcchd.2024.100516","DOIUrl":"10.1016/j.ijcchd.2024.100516","url":null,"abstract":"","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000259/pdfft?md5=7e8c24930838ac591e8818be10f03cb9&pid=1-s2.0-S2666668524000259-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology” [Int J Cardiol Congenit Heart Dis, Volume 7, March 2022, 100331] 运动通气储备可预测艾森曼格生理学成人先天性心脏病伴肺动脉高压患者的存活率》更正[《Int J Cardiol Congenit Heart Dis》,第 7 卷,2022 年 3 月,100331]
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.ijcchd.2024.100517
{"title":"Corrigendum to “Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology” [Int J Cardiol Congenit Heart Dis, Volume 7, March 2022, 100331]","authors":"","doi":"10.1016/j.ijcchd.2024.100517","DOIUrl":"10.1016/j.ijcchd.2024.100517","url":null,"abstract":"","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000260/pdfft?md5=b5f51d470f3eb3a097cff16c48d3dd74&pid=1-s2.0-S2666668524000260-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142151314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel techniques for quantifying oxygen pulse curve characteristics during cardiopulmonary exercise testing in tetralogy of fallot 在法洛氏四联症心肺运动测试中量化氧脉搏曲线特征的新技术
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 DOI: 10.1016/j.ijcchd.2024.100539

Background

Cardiopulmonary exercise testing (CPET) is used in evaluation of repaired tetralogy of Fallot (rTOF), particularly for pulmonary valve replacement need. Oxygen pulse (O2P) is the CPET surrogate for stroke volume and peripheral oxygen extraction.

Objectives

This study assessed O2P curve properties against non-invasive cardiac output monitoring (NICOM) and clinical testing.

Methods

This cross-sectional study included 44 rTOF patients and 10 controls. Three new evaluations for O2P curve analysis during CPET were developed. Best fit early and late regression slopes of the O2P curve were used to calculate: 1) the early to late ratio, or “O2 pulse response ratio” (O2PRR); 2) the portion of exercise until slope inflection, or “flattening fraction” (FF); 3) the area under the O2P response curve, or “O2P curve area”.

Results

rTOF patients (median age 35.2 (27.6–39.4); 61% female) had a lower VO2 max (23.4 vs 45.6 ml/kg/min; p < 0.001) and O2P max (11.5 vs 19.1 ml/beat; p < 0.001) compared to controls. Those with a FF occurring <50% through exercise had a lower peak cardiac index and stroke volume, but not VO2 max, compared to those >50%. FF and O2P curve area significantly correlated with peak cardiac index, stroke volume, left and right ventricular ejection fraction, and right ventricular systolic pressure.

Conclusion

CPET remains an integral part in the evaluation of rTOF. We introduce three non-invasive methods to assess exercise hemodynamics using the O2P curve data. These evaluations demonstrated significant correlations with stroke volume, cardiac output, and right ventricular pressure.

背景心肺运动测试(CPET)用于评估法洛氏四联症(rTOF)的修复情况,尤其是肺动脉瓣置换的需要。氧脉搏(O2P)是 CPET 中每搏量和外周氧萃取的代用指标。本研究评估了 O2P 曲线与无创心输出量监测(NICOM)和临床测试的对比特性。为 CPET 期间的 O2P 曲线分析开发了三种新的评估方法。利用 O2P 曲线早期和晚期的最佳拟合回归斜率来计算:1)早期和晚期比值;2)早期和晚期比值;3)早期和晚期比值:1)早期与晚期之比,即 "O2 脉冲响应比"(O2PRR);2)运动至斜率拐点的部分,即 "平坦化分数"(FF);3)O2P 响应曲线下的面积,即 "O2P 曲线面积"。结果rTOF 患者(中位年龄 35.2 (27.6-39.4); 61% 女性)与对照组相比,最大 VO2 值(23.4 vs 45.6 ml/kg/min;p <;0.001)和最大 O2P 值(11.5 vs 19.1 ml/beat;p <;0.001)较低。在运动过程中FF达到50%的人与达到50%的人相比,峰值心脏指数和每搏容量较低,但最大氧饱和度却不低。FF和O2P曲线面积与峰值心脏指数、每搏量、左室和右室射血分数以及右室收缩压显著相关。我们介绍了使用 O2P 曲线数据评估运动血流动力学的三种无创方法。这些评估结果表明,它们与每搏量、心输出量和右心室压力有明显的相关性。
{"title":"Novel techniques for quantifying oxygen pulse curve characteristics during cardiopulmonary exercise testing in tetralogy of fallot","authors":"","doi":"10.1016/j.ijcchd.2024.100539","DOIUrl":"10.1016/j.ijcchd.2024.100539","url":null,"abstract":"<div><h3>Background</h3><p>Cardiopulmonary exercise testing (CPET) is used in evaluation of repaired tetralogy of Fallot (rTOF), particularly for pulmonary valve replacement need. Oxygen pulse (O<sub>2</sub>P) is the CPET surrogate for stroke volume and peripheral oxygen extraction.</p></div><div><h3>Objectives</h3><p>This study assessed O<sub>2</sub>P curve properties against non-invasive cardiac output monitoring (NICOM) and clinical testing.</p></div><div><h3>Methods</h3><p>This cross-sectional study included 44 rTOF patients and 10 controls. Three new evaluations for O<sub>2</sub>P curve analysis during CPET were developed. Best fit early and late regression slopes of the O<sub>2</sub>P curve were used to calculate: 1) the early to late ratio, or “O<sub>2</sub> pulse response ratio” (O<sub>2</sub>PRR); 2) the portion of exercise until slope inflection, or “flattening fraction” (FF); 3) the area under the O<sub>2</sub>P response curve, or “O<sub>2</sub>P curve area”.</p></div><div><h3>Results</h3><p>rTOF patients (median age 35.2 (27.6–39.4); 61% female) had a lower VO<sub>2</sub> max (23.4 vs 45.6 ml/kg/min; p &lt; 0.001) and O<sub>2</sub>P max (11.5 vs 19.1 ml/beat; p &lt; 0.001) compared to controls. Those with a FF occurring &lt;50% through exercise had a lower peak cardiac index and stroke volume, but not VO<sub>2</sub> max, compared to those &gt;50%. FF and O<sub>2</sub>P curve area significantly correlated with peak cardiac index, stroke volume, left and right ventricular ejection fraction, and right ventricular systolic pressure.</p></div><div><h3>Conclusion</h3><p>CPET remains an integral part in the evaluation of rTOF. We introduce three non-invasive methods to assess exercise hemodynamics using the O<sub>2</sub>P curve data. These evaluations demonstrated significant correlations with stroke volume, cardiac output, and right ventricular pressure.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266666852400048X/pdfft?md5=7b84ac15bd2ec21c11b5fb7d8a372d86&pid=1-s2.0-S266666852400048X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A national Australian Congenital Heart Disease registry; methods and initial results 澳大利亚全国先天性心脏病登记;方法和初步结果
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-24 DOI: 10.1016/j.ijcchd.2024.100538

Background

Although several National Data Registries for Congenital Heart Disease (CHD) exist, few are comprehensive and contemporary. A National Australian CHD Registry has been developed that aims to redress this by creating the first comprehensive data collection for CHD children and adults, initially across Australia.

Methods

We defined and collected a minimum dataset of demographics, diagnoses, and procedures from people with CHD presenting at participating quaternary CHD services Australia-wide. Data were collected from a range of clinical data sources. Diagnoses and procedures were standardised to the European Paediatric Congenital Code – Short List. Methodological limitations were carefully documented.

Results

From 8 participating institutions, an initial 359,084 patient records were assessed for eligibility and 68,234 unique individuals with structural CHD have been included in the current dataset. There were 20,395 (30 %) people with mild CHD, 25,157 (37 %) with moderate CHD, and 13,530 (20 %) with severe CHD (6 % unknown complexity). The most common diagnoses were Ventricular Septal Defect (16,781, 25 %), Atrial Septal Defect (6,607, 10 %), Aortic Valve Disorders (5516 8 %), Coarctation of the Aorta (5,321, 8 %), Tetralogy of Fallot (4,489, 7 %), Transposition of the Great Arteries (4,009, 6 %).

Conclusion

The data presented here represents the most comprehensive cohort collected for the Australian CHD population thus far and is comparable with the largest contemporary CHD registries around the world. This Registry represents a key resource for improved understanding of the CHD population and will drive better care and outcomes for people living with CHD.

背景虽然目前已有多个国家先天性心脏病(CHD)数据登记处,但很少有登记处是全面和现代的。澳大利亚国家先天性心脏病登记处(National Australian CHD Registry)已经建立,旨在通过首次在全澳范围内全面收集先天性心脏病儿童和成人的数据来解决这一问题。方法我们定义并收集了在全澳范围内参与的四级先天性心脏病服务机构就诊的先天性心脏病患者的最低人口统计学、诊断和手术数据集。数据收集自一系列临床数据源。诊断和手术均按照《欧洲儿科先天性疾病代码--简表》进行标准化。结果8家参与机构的359,084份病历通过了初步资格评估,68,234名结构性先天性心脏病患者被纳入当前数据集中。其中,20,395 人(30%)患有轻度先天性心脏病,25,157 人(37%)患有中度先天性心脏病,13,530 人(20%)患有重度先天性心脏病(6%复杂程度未知)。最常见的诊断是室间隔缺损(16781 人,25%)、心房隔缺损(6607 人,10%)、主动脉瓣疾病(5516 人,8%)、主动脉共动脉症(5321 人,8%)、法洛氏四联症(4489 人,7%)、大动脉转位(4009 人,6%)。结论本文提供的数据是迄今为止收集到的最全面的澳大利亚先天性心脏病人群队列数据,可与全球最大的当代先天性心脏病登记处的数据相媲美。该登记处是增进对冠心病人群了解的重要资源,将推动为冠心病患者提供更好的护理和治疗效果。
{"title":"A national Australian Congenital Heart Disease registry; methods and initial results","authors":"","doi":"10.1016/j.ijcchd.2024.100538","DOIUrl":"10.1016/j.ijcchd.2024.100538","url":null,"abstract":"<div><h3>Background</h3><p>Although several National Data Registries for Congenital Heart Disease (CHD) exist, few are comprehensive and contemporary. A National Australian CHD Registry has been developed that aims to redress this by creating the first comprehensive data collection for CHD children and adults, initially across Australia.</p></div><div><h3>Methods</h3><p>We defined and collected a minimum dataset of demographics, diagnoses, and procedures from people with CHD presenting at participating quaternary CHD services Australia-wide. Data were collected from a range of clinical data sources. Diagnoses and procedures were standardised to the European Paediatric Congenital Code – Short List. Methodological limitations were carefully documented.</p></div><div><h3>Results</h3><p>From 8 participating institutions, an initial 359,084 patient records were assessed for eligibility and 68,234 unique individuals with structural CHD have been included in the current dataset. There were 20,395 (30 %) people with mild CHD, 25,157 (37 %) with moderate CHD, and 13,530 (20 %) with severe CHD (6 % unknown complexity). The most common diagnoses were Ventricular Septal Defect (16,781, 25 %), Atrial Septal Defect (6,607, 10 %), Aortic Valve Disorders (5516 8 %), Coarctation of the Aorta (5,321, 8 %), Tetralogy of Fallot (4,489, 7 %), Transposition of the Great Arteries (4,009, 6 %).</p></div><div><h3>Conclusion</h3><p>The data presented here represents the most comprehensive cohort collected for the Australian CHD population thus far and is comparable with the largest contemporary CHD registries around the world. This Registry represents a key resource for improved understanding of the CHD population and will drive better care and outcomes for people living with CHD.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000478/pdfft?md5=f7a86b652a555e39ec405957490f69c7&pid=1-s2.0-S2666668524000478-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142075884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging in chronic thromboembolic pulmonary disease: Current practice and advances 慢性血栓栓塞性肺病的成像:当前实践与进展
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-10 DOI: 10.1016/j.ijcchd.2024.100536

Chronic thromboembolic pulmonary disease (CTEPD) with or without pulmonary hypertension (PH) occurs when thromboemboli in pulmonary arteries fail to resolve completely. Pulmonary artery obstructions due to chronic thrombi and secondary microvasculopathy can increase pulmonary arterial pressure and resistance leading to chronic thromboembolic PH (CTEPH). Mechanical interventions and/or PH medications can improve cardiopulmonary haemodynamic, alleviate symptoms, and decrease mortality risk. Imaging is pivotal throughout the CTEPD management journey, spanning diagnosis, treatment planning, and assessing treatment outcome. With just computed tomography (CT) pulmonary angiogram and right heart catheterisation, an experienced multidisciplinary team can determine surgical candidacy in most cases. Dual energy CT, lung subtraction iodine mapping CT, and dynamic contrast-enhanced magnetic resonance imaging (MRI) offer comparable sensitivities with ventilation-perfusion scintigraphy in diagnosing CTEPD. Pulmonary angiogram with digital subtraction angiography although considered the gold standard for assessing thrombi extent and vasculature morphology is now mostly used to assess targets for balloon pulmonary angioplasty. Advancements in CT modalities and innovative MRI metrics offer better insight into CTEPD management but are limited by the availability of technology and expertise. Learning from current artificial intelligence application in medical imaging, there is promise in tapping the wealth of data provided by CTEPD imaging through automating cardiopulmonary and vascular morphology analysis.

当肺动脉中的血栓栓塞未能完全消退时,就会发生伴有或不伴有肺动脉高压(PH)的慢性血栓栓塞性肺病(CTEPD)。慢性血栓和继发性微血管病变造成的肺动脉阻塞会增加肺动脉压力和阻力,导致慢性血栓栓塞性肺动脉高压(CTEPH)。机械干预和/或 PH 药物可改善心肺血流动力学、缓解症状并降低死亡风险。在 CTEPD 的整个治疗过程中,影像学在诊断、治疗计划和治疗效果评估方面都起着至关重要的作用。只需进行计算机断层扫描(CT)肺血管造影和右心导管检查,经验丰富的多学科团队就能确定大多数病例是否适合手术。双能量 CT、肺减影碘映射 CT 和动态对比增强磁共振成像(MRI)在诊断 CTEPD 方面的灵敏度与通气-灌注闪烁成像相当。虽然数字减影血管造影被认为是评估血栓范围和血管形态的金标准,但目前主要用于评估球囊肺血管成形术的目标。CT 模式和创新磁共振成像指标的进步为 CTEPD 的管理提供了更好的视角,但受限于技术和专业知识的可用性。借鉴当前人工智能在医学影像领域的应用,通过自动化心肺和血管形态分析,有望利用 CTEPD 成像提供的丰富数据。
{"title":"Imaging in chronic thromboembolic pulmonary disease: Current practice and advances","authors":"","doi":"10.1016/j.ijcchd.2024.100536","DOIUrl":"10.1016/j.ijcchd.2024.100536","url":null,"abstract":"<div><p>Chronic thromboembolic pulmonary disease (CTEPD) with or without pulmonary hypertension (PH) occurs when thromboemboli in pulmonary arteries fail to resolve completely. Pulmonary artery obstructions due to chronic thrombi and secondary microvasculopathy can increase pulmonary arterial pressure and resistance leading to chronic thromboembolic PH (CTEPH). Mechanical interventions and/or PH medications can improve cardiopulmonary haemodynamic, alleviate symptoms, and decrease mortality risk. Imaging is pivotal throughout the CTEPD management journey, spanning diagnosis, treatment planning, and assessing treatment outcome. With just computed tomography (CT) pulmonary angiogram and right heart catheterisation, an experienced multidisciplinary team can determine surgical candidacy in most cases. Dual energy CT, lung subtraction iodine mapping CT, and dynamic contrast-enhanced magnetic resonance imaging (MRI) offer comparable sensitivities with ventilation-perfusion scintigraphy in diagnosing CTEPD. Pulmonary angiogram with digital subtraction angiography although considered the gold standard for assessing thrombi extent and vasculature morphology is now mostly used to assess targets for balloon pulmonary angioplasty. Advancements in CT modalities and innovative MRI metrics offer better insight into CTEPD management but are limited by the availability of technology and expertise. Learning from current artificial intelligence application in medical imaging, there is promise in tapping the wealth of data provided by CTEPD imaging through automating cardiopulmonary and vascular morphology analysis.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000454/pdfft?md5=00d52e64d87991bb3e2bcda91db0bbb9&pid=1-s2.0-S2666668524000454-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141991426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The latest definition and classification of pulmonary hypertension 肺动脉高压的最新定义和分类
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-31 DOI: 10.1016/j.ijcchd.2024.100534

Pulmonary hypertension (PH) is a serious potential complication of some congenital heart diseases (CHDs). PH encompasses a range of diseases which may be idiopathic or inherited, or secondary to cardiac, respiratory, systemic or thromboembolic conditions, amongst others. Our increasing understanding of the normal ranges of pulmonary haemodynamics, as well as evidence supporting the benefits of early treatment, has resulted in a number of recent revisions to the haemodynamic definition of PH. In this Review Article, we report on the recent updates to haemodynamic definitions and classification of PH, as reflected in the 2022 Pulmonary Hypertension Guidelines and particularly focus on the CHD related sub-type of PH, where the aetiology is often multi-factorial.

肺动脉高压(PH)是某些先天性心脏病(CHD)的严重潜在并发症。肺动脉高压包括一系列疾病,可能是特发性或遗传性的,也可能是继发于心脏、呼吸、全身或血栓栓塞等疾病。我们对肺血流动力学正常范围的认识不断加深,同时有证据表明早期治疗有益,因此最近对 PH 的血流动力学定义进行了多次修订。在这篇综述文章中,我们将报告 2022 年《肺动脉高压指南》中对 PH 的血流动力学定义和分类的最新更新,并特别关注 PH 的冠心病相关亚型,因为其病因通常是多因素的。
{"title":"The latest definition and classification of pulmonary hypertension","authors":"","doi":"10.1016/j.ijcchd.2024.100534","DOIUrl":"10.1016/j.ijcchd.2024.100534","url":null,"abstract":"<div><p>Pulmonary hypertension (PH) is a serious potential complication of some congenital heart diseases (CHDs). PH encompasses a range of diseases which may be idiopathic or inherited, or secondary to cardiac, respiratory, systemic or thromboembolic conditions, amongst others. Our increasing understanding of the normal ranges of pulmonary haemodynamics, as well as evidence supporting the benefits of early treatment, has resulted in a number of recent revisions to the haemodynamic definition of PH. In this Review Article, we report on the recent updates to haemodynamic definitions and classification of PH, as reflected in the 2022 Pulmonary Hypertension Guidelines and particularly focus on the CHD related sub-type of PH, where the aetiology is often multi-factorial.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000430/pdfft?md5=2f474a94fabfc36da592cb9b263a8b26&pid=1-s2.0-S2666668524000430-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141962033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subpulmonary ventricular function and inflammation are related to clinical heart failure in patients with a systemic right ventricle 肺下心室功能和炎症与系统性右心室患者的临床心力衰竭有关
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-31 DOI: 10.1016/j.ijcchd.2024.100535

Background

Timely diagnosis of heart failure (HF) in patients with a systemic right ventricle (sRV) is difficult but important since clinical deterioration is fast once HF develops. We aimed to compare echocardiography and biomarker profile between sRV patients with and without HF and patients with a systemic left ventricle diagnosed with HF (sLV-HF).

Methods and results

Eighty-seven sRV patients and 30 sLV-HF patients underwent echocardiographic evaluation and blood sampling. Compared to sRV patients without HF, sRV-HF patients had more remodeling of the subpulmonary LV (spLV) (internal diameter 3.9 cm [3.3–5.7] vs 3.4 cm [2.9–3.9], P = 0.03, posterior wall 0.93 cm [0.76–1.20] vs 0.71 cm [0.59–0.91], P = 0.006) and lower spLV systolic function: ejection fraction (59 % ± 14 vs 70 % ± 10, P = 0.011), mitral annular plane systolic excursion (1.7 cm ± 0.5 vs 2.1 cm ± 0.4, P = 0.003), fractional area change (47 % [38–58] vs 59 % [51–70], P = 0.002) and lateral strain rate (−1.2/s ± 0.46 vs −1.5/s ± 0.39, P = 0.016). Inflammatory biomarkers were higher in sRV-HF patients compared to those without HF: red cell distribution width (13.3 fL [12.8–14.1] vs 12.6 fL [12.3–13.1], P < 0.001), neutrophil lymphocyte ratio (NLR, 3.7 [2.2–4.9] vs 2.4 [1.9–3.0], P = 0.015), C-reactive protein (CRP, 2.5 mg/dL [1.0–4.2] vs 1.2 mg/dL [0.0–2.0], P = 0.005) and compared to sLV-HF patients (NLR (3.7 [2.2–4.9] vs 2.5 [1.7–3.3], P = 0.044) and CRP (2.5 mg/dL [1.0–4.2] vs 0.85 mg/dL [0.6–2.0], P = 0.006).

Conclusion

Biventricular echocardiographic evaluation with a focus on the subpulmonary LV together with assessing inflammatory status in sRV patients could help in an earlier detection of HF.

背景及时诊断全身性右心室(sRV)患者的心力衰竭(HF)很困难,但却很重要,因为一旦发生 HF,临床症状会迅速恶化。我们旨在比较伴有和不伴有心力衰竭的 sRV 患者与确诊为心力衰竭的全身性左心室患者(sLV-HF)之间的超声心动图和生物标志物谱。与无 HF 的 sRV 患者相比,sRV-HF 患者的肺下左心室(spLV)重塑程度更高(内径 3.9 cm [3.3-5.7] vs 3.4 cm [2.9-3.9],P = 0.03,后壁 0.93 cm [0.76-1.20] vs 0.71 cm [0.59-0.91],P = 0.006])和较低的二尖瓣收缩功能:射血分数(59 % ± 14 vs 70 % ± 10,P = 0.011)、二尖瓣瓣环平面收缩期偏移(1.7 cm ± 0.5 vs 2.1 cm ± 0.4,P = 0.003)、分数面积变化(47 % [38-58] vs 59 % [51-70],P = 0.002)和侧向应变率(-1.2/s ± 0.46 vs -1.5/s ± 0.39,P = 0.016)。与非 HF 患者相比,sRV-HF 患者的炎症生物标志物更高:红细胞分布宽度(13.3 fL [12.8-14.1] vs 12.6 fL [12.3-13.1],P < 0.001)、中性粒细胞淋巴细胞比值(NLR,3.7 [2.2-4.9] vs 2.4 [1.9-3.0],P = 0.015)、C反应蛋白(CRP,2.5 mg/dL [1.0-4.2] vs 1.2 mg/dL [0.0-2.0],P = 0.005),与 sLV-HF 患者相比(NLR(3.7 [2.2-4.9] vs 2.5 [1.7-3.3],P = 0.044)和 CRP(2.5 mg/dL [1.0-4.2] vs 0.85 mg/dL [0.6-2.0],P = 0.006)。
{"title":"Subpulmonary ventricular function and inflammation are related to clinical heart failure in patients with a systemic right ventricle","authors":"","doi":"10.1016/j.ijcchd.2024.100535","DOIUrl":"10.1016/j.ijcchd.2024.100535","url":null,"abstract":"<div><h3>Background</h3><p>Timely diagnosis of heart failure (HF) in patients with a systemic right ventricle (sRV) is difficult but important since clinical deterioration is fast once HF develops. We aimed to compare echocardiography and biomarker profile between sRV patients with and without HF and patients with a systemic left ventricle diagnosed with HF (sLV-HF).</p></div><div><h3>Methods and results</h3><p>Eighty-seven sRV patients and 30 sLV-HF patients underwent echocardiographic evaluation and blood sampling. Compared to sRV patients without HF, sRV-HF patients had more remodeling of the subpulmonary LV (spLV) (internal diameter 3.9 cm [3.3–5.7] vs 3.4 cm [2.9–3.9], P = 0.03, posterior wall 0.93 cm [0.76–1.20] vs 0.71 cm [0.59–0.91], P = 0.006) and lower spLV systolic function: ejection fraction (59 % ± 14 vs 70 % ± 10, P = 0.011), mitral annular plane systolic excursion (1.7 cm ± 0.5 vs 2.1 cm ± 0.4, P = 0.003), fractional area change (47 % [38–58] vs 59 % [51–70], P = 0.002) and lateral strain rate (−1.2/s ± 0.46 vs −1.5/s ± 0.39, P = 0.016). Inflammatory biomarkers were higher in sRV-HF patients compared to those without HF: red cell distribution width (13.3 fL [12.8–14.1] vs 12.6 fL [12.3–13.1], P &lt; 0.001), neutrophil lymphocyte ratio (NLR, 3.7 [2.2–4.9] vs 2.4 [1.9–3.0], P = 0.015), C-reactive protein (CRP, 2.5 mg/dL [1.0–4.2] vs 1.2 mg/dL [0.0–2.0], P = 0.005) and compared to sLV-HF patients (NLR (3.7 [2.2–4.9] vs 2.5 [1.7–3.3], P = 0.044) and CRP (2.5 mg/dL [1.0–4.2] vs 0.85 mg/dL [0.6–2.0], P = 0.006).</p></div><div><h3>Conclusion</h3><p>Biventricular echocardiographic evaluation with a focus on the subpulmonary LV together with assessing inflammatory status in sRV patients could help in an earlier detection of HF.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000442/pdfft?md5=98391a18df1fea3bb58f2b154788fef1&pid=1-s2.0-S2666668524000442-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141991425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes, mortality risk factors, and functional status post-Norwood: A single-center study 结果、死亡率风险因素和诺伍德后的功能状态:单中心研究
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-26 DOI: 10.1016/j.ijcchd.2024.100533

Background

The Norwood operation (NO) for infants with univentricular physiology has high interstage mortality. This study evaluated outcomes and risk factors for mortality following NO.

Methods

Retrospective single-center study of patients undergoing NO from 2010 to 2020. Analysis used appropriate statistics.

Results

Of 269 patients undergoing NO, 213 (79.2 %) survived to discharge. Non-survivors had longer bypass times, delayed sternal closure, required nitric oxide, higher vasoactive scores, required post-operative catheterization, Extracorporeal Life Support (ECLS), and longer ventilation (p < 0.05). Logistic regression showed moderate-severe atrioventricular valve regurgitation on intraoperative TEE (OR 2.6), requiring nitric oxide (OR 2.63), delayed sternal closure (OR 2.94), post-operative catheterization (OR 10.48), and ECLS (OR 14.54) increased mortality odds (p < 0.05). Multivariable analysis confirmed catheterization (aOR 10.48) and ECLS (aOR 14.54) as significant predictors. Of survivors, 26 (12.3 %) developed new morbidity, 9 (4.2 %) had unfavorable outcomes. Functional status improved from 6.0 to 8.04, mainly in feeding and respiratory domains (p < 0.0001).

Conclusions

Norwood survival was 79.2 %. Requiring post-operative catheterization and ECLS significantly increased mortality risk. Multicenter evaluation of these modifiable risk factors is needed to improve outcomes in this high-risk population.

背景诺伍德手术(Norwood operation,NO)用于治疗单心室生理的婴儿,其阶段间死亡率很高。本研究评估了诺伍德手术后的结果和死亡风险因素。方法对 2010 年至 2020 年接受诺伍德手术的患者进行单中心回顾性研究。结果 在269名接受无创手术的患者中,213人(79.2%)存活至出院。非存活患者的旁路时间更长、胸骨闭合延迟、需要一氧化氮、血管活性评分更高、需要术后导管插入、体外生命支持(ECLS)和通气时间更长(p <0.05)。逻辑回归显示,术中 TEE 显示的中重度房室瓣反流(OR 2.6)、需要一氧化氮(OR 2.63)、延迟胸骨闭合(OR 2.94)、术后导管插入(OR 10.48)和体外生命支持(ECLS)(OR 14.54)增加了死亡率几率(p < 0.05)。多变量分析证实导管插入术(aOR 10.48)和 ECLS(aOR 14.54)是重要的预测因素。在幸存者中,26 人(12.3%)出现了新的病症,9 人(4.2%)出现了不良后果。功能状态从 6.0 改善到 8.04,主要是在进食和呼吸领域(p < 0.0001)。结论诺伍德的存活率为 79.2%,术后需要导管插入术和 ECLS 会显著增加死亡风险。需要对这些可改变的风险因素进行多中心评估,以改善这一高风险人群的预后。
{"title":"Outcomes, mortality risk factors, and functional status post-Norwood: A single-center study","authors":"","doi":"10.1016/j.ijcchd.2024.100533","DOIUrl":"10.1016/j.ijcchd.2024.100533","url":null,"abstract":"<div><h3>Background</h3><p>The Norwood operation (NO) for infants with univentricular physiology has high interstage mortality. This study evaluated outcomes and risk factors for mortality following NO.</p></div><div><h3>Methods</h3><p>Retrospective single-center study of patients undergoing NO from 2010 to 2020. Analysis used appropriate statistics.</p></div><div><h3>Results</h3><p>Of 269 patients undergoing NO, 213 (79.2 %) survived to discharge. Non-survivors had longer bypass times, delayed sternal closure, required nitric oxide, higher vasoactive scores, required post-operative catheterization, Extracorporeal Life Support (ECLS), and longer ventilation (p &lt; 0.05). Logistic regression showed moderate-severe atrioventricular valve regurgitation on intraoperative TEE (OR 2.6), requiring nitric oxide (OR 2.63), delayed sternal closure (OR 2.94), post-operative catheterization (OR 10.48), and ECLS (OR 14.54) increased mortality odds (p &lt; 0.05). Multivariable analysis confirmed catheterization (aOR 10.48) and ECLS (aOR 14.54) as significant predictors. Of survivors, 26 (12.3 %) developed new morbidity, 9 (4.2 %) had unfavorable outcomes. Functional status improved from 6.0 to 8.04, mainly in feeding and respiratory domains (p &lt; 0.0001).</p></div><div><h3>Conclusions</h3><p>Norwood survival was 79.2 %. Requiring post-operative catheterization and ECLS significantly increased mortality risk. Multicenter evaluation of these modifiable risk factors is needed to improve outcomes in this high-risk population.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000429/pdfft?md5=e08ecc7ded54dee64f3ee71a698dc086&pid=1-s2.0-S2666668524000429-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare presentation of pulmonary hypertension 肺动脉高压的罕见表现
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-25 DOI: 10.1016/j.ijcchd.2024.100531
{"title":"A rare presentation of pulmonary hypertension","authors":"","doi":"10.1016/j.ijcchd.2024.100531","DOIUrl":"10.1016/j.ijcchd.2024.100531","url":null,"abstract":"","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000405/pdfft?md5=b334fb2d0d62ee8f246900eb7b6d82f6&pid=1-s2.0-S2666668524000405-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital heart defects and consanguinity: An analysis of the Sidra cardiac registry data in Qatar 先天性心脏缺陷与血缘关系:卡塔尔 Sidra 心脏登记数据分析
IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-20 DOI: 10.1016/j.ijcchd.2024.100529
{"title":"Congenital heart defects and consanguinity: An analysis of the Sidra cardiac registry data in Qatar","authors":"","doi":"10.1016/j.ijcchd.2024.100529","DOIUrl":"10.1016/j.ijcchd.2024.100529","url":null,"abstract":"","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000387/pdfft?md5=01a3dbe06445fd5b7d931a8f94fef8a3&pid=1-s2.0-S2666668524000387-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of cardiology. Congenital heart disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1